The use of bioisosteric groups in lead optimization.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Pharmacology

Background:

• Bioisosterism, the concept of similar biological activity in structurally related compounds, was introduced by Friedman fifty years ago.
• The principle of bioisosterism has been widely applied in drug discovery for lead compound optimization.
• Recent advances in recombinant protein expression and high-throughput screening have expanded the pool of potential drug targets.

Purpose of the Study:

• To highlight the significant value of bioisosteric replacement in fine-tuning lead compounds for clinical development.
• To emphasize the utility of bioisosterism in improving drug selectivity and pharmacokinetic profiles.
• To illustrate the application of bioisosteres in lead optimization with recent literature examples.

Main Methods:

• Literature review of recent examples showcasing bioisosteric replacement in drug discovery.
• Analysis of the role of bioisosterism in optimizing lead compound properties.
• Focus on applications in enhancing target selectivity and pharmacokinetic parameters.

Main Results:

• Bioisosteric replacement is a powerful tool for optimizing lead compounds, particularly for clinical suitability.
• The strategy effectively improves selectivity for specific biological targets.
• Pharmacokinetic properties of lead compounds can be significantly enhanced through bioisosteric modifications.

Conclusions:

• Bioisosteric replacement remains a crucial and effective strategy in modern drug discovery and development.
• Its application is vital for refining drug candidates to meet the rigorous demands of clinical trials.
• The judicious use of bioisosteres contributes to the successful optimization of drug properties, including selectivity and pharmacokinetics.